Base
RuleSignificant2024-016932024-02-02

Medications for the Treatment of Opioid Use Disorder

Health and Human Services Department,

Abstract

This final rule modifies and updates certain provisions of regulations related to Opioid Treatment Program (OTP) accreditation, certification, and standards for the treatment of Opioid Use Disorder (OUD) with Medications for Opioid Use Disorder (MOUD) in OTPs. This includes making flexibilities put forth during the COVID-19 Public Health Emergency (PHE) permanent, as well as expanding access to care and evidence-based treatment for OUD. The final rule also removes all language and rules pertaining to the Drug Addiction and Treatment Act (DATA) Waiver from the regulations pursuant to the "Consolidated Appropriations Act, 2023".

Action & Dates

Action
Final rule.
Dates
The effective date of this final rule is April 2, 2024, and the compliance date is October 2, 2024.
Effective Date
2024-04-02

CFR References

Topics

Administrative practice and procedureHealth professionsReporting and recordkeeping requirements

Document Excerpt

Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Health and Human Services Office of the Secretary 42 CFR Part 8 RIN 0930-AA39 AGENCY: Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services (“HHS” or “the Department”). ACTION: Final rule. SUMMARY: This final rule modifies and updates certain provisions of regulations related to Opioid Treatment Program (OTP) accreditation, certification, and standards for the treatment of Opioid Use Disorder (OUD) with Medications for Opioid Use Disorder (MOUD) in OTPs. This includes making flexibilities put forth during the COVID-19 Public Health Emergency (PHE) permanent, as well as expanding access to care and evidence-based treatment for OUD. The final rule also removes all language and rules pertaining to the Drug Addiction and Treatment Act (DATA) Waiver from the regulations pursuant to the “Consolidated Appropriations Act, 2023”. DATES: The effective date of this final rule is April 2, 2024, and the compliance date is October 2, 2024. FOR FURTHER INFORMATION CONTACT: Robert Baillieu, MD, MPH, Physician and Senior Advisor, SAMHSA/CSAT, 5600 Fishers Lane, Room 13-E-30, Rockville, MD, 20857, Phone: 202-923-0996, Email: Robert.Baillieu@samhsa.hhs.gov . SUPPLEMENTARY INFORMATION: The discussion below includes an Executive Summary and overview describing the rule, responses to public comments, an impact statement, and other required regulatory analyses. Executive Summary A. Overview This

Read full document on FederalRegister.gov →

Full Document

Citation: 89 FR 7528